This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Glaukos Stock in Your Portfolio
by Zacks Equity Research
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
Is Franklin U.S. Mid Cap Multifactor Index ETF (FLQM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FLQM
Here's Why You Should Add Hims & Hers Stock to Your Portfolio Now
by Zacks Equity Research
Hims & Hers leads with AI-powered, personalized health plans (over 70% of new users opt in). Recurring revenues surge as tailored care drives loyalty.
MCK Stock Gains More Than 4% Following Strong Q4: Should You Buy Now?
by Indrajit Bandyopadhyay
McKesson's strong fundamentals are likely to keep it ahead of the competition. Should investors add it to their portfolio now?
Here's Why You Should Add DexCom Stock to Your Portfolio Now
by Zacks Equity Research
DXCM continues to raise investor optimism due to its strong product portfolio.
Doximity Stock Plunges Despite Q4 Earnings & Sales Beat, Margins Up
by Zacks Equity Research
DOCS reports robust growth in unique active users and sales of workflow tools, driving the top and bottom lines. First-quarter fiscal 2026 sales outlook below estimates.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
Should Franklin U.S. Mid Cap Multifactor Index ETF (FLQM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FLQM
Beat the Market the Zacks Way: Limbach, Stride, Cencora in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Here's Why Cencora (COR) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Cencora (COR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised
by Zacks Equity Research
COR's second-quarter fiscal 2025 results showcase a strong segmental performance. The company's earnings guidance for fiscal 2025 looks encouraging.
Has BrightSpring Health Services, Inc. (BTSG) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how BrightSpring Health Services, Inc. (BTSG) and Cencora (COR) have performed compared to their sector so far this year.
Cencora (COR) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Cencora (COR) delivered earnings and revenue surprises of 8.33% and 0.85%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Earnings to Watch on May 7: COR, QDEL & INGN
by Harshit Gupta
The medical device industry is growing fast in 2025, but faces supply and trade issues. Major companies are set to report earnings on May 7, stay tuned!
Is First Trust Growth Strength ETF (FTGS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FTGS
DENTSPLY SIRONA to Post Q1 Earnings: What's in Store for the Stock?
by Zacks Equity Research
XRAY is likely to have faced a tough first quarter with Byte's revenue loss, weak U.S. equipment demands and implant pressures.
Will Speciality and GLP-1 Drugs Help COR Beat Q2 Earnings Estimates?
by Zacks Equity Research
COR's fiscal second-quarter results are likely to reflect decent U.S. Healthcare Solutions segmental performance.
Should You Buy, Sell, or Hold FMS Stock Before Q1 Earnings?
by Zacks Equity Research
Fresenius Medical Care heads into the first quarter of 2025 with momentum from cost savings, innovation like the 5008X launch, and a steady recovery in U.S. treatment volumes.
Unveiling Cencora (COR) Q2 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Cencora (COR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
Will Declining Medical Customers Affect Cigna's Q1 Earnings?
by Zacks Equity Research
CI's first-quarter results are likely to have benefited from growing pharmacy revenues and fees.
Cencora (COR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Can Humana Beat Q1 Earnings Estimates on Growing Premiums?
by Zacks Equity Research
HUM's first-quarter results are likely to benefit from higher Medicare stand-alone PDP revenues.